Global pharma major Lupin Limited (Lupin) announced the launch of combination drug sacubitril and valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with heart failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million. In addition, the HF pattern in India is considered different from the rest of the world due to factors such as the average age of Indian patients with HF being 10 years younger than the global average, the high prevalence of hypertension and diabetes, and limited adoption of guideline-directed medical therapy, among others. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure. Commenting on the launch, Rajeev Sibal, president
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!